MedTrace Logo

Bioavailability and Effectiveness of Transdermally Administered Morphine

NCT00125684 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2012-01-19

No results posted yet for this study

Summary

Patients will participate in two arms of the trial, one in which morphine will be administered transdermally, and, after a 3 day wash out period, one in which morphine will be administered subcutaneously.

Conditions

Interventions

DRUG

morphine

Sponsors & Collaborators

  • Tom Baker Cancer Centre

    collaborator OTHER

  • Alberta Health services

    lead OTHER

Principal Investigators

  • Neil Hagen · Alberta Cancerboard

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-07-31
Primary Completion
2007-07-31
Completion
2008-07-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00125684 on ClinicalTrials.gov